IMVARIA
The AI engine Fit Assessment
BetaIMVARIA leverages machine learning to enhance patient outcomes through novel pattern discovery and the expansion of therapeutics, focusing on digital biomarker identification.
Blurb
HQ Location
Founded
Employees
Total funding raised
Last Funding Event
Smart insights
- Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
- Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
- 6m headcount growth: 25%
- 1Y headcount growth: 94%
- Headcount-to-last-round ratio: 5.3 employees/$M
- Biomarker Identification
IMVARIA is advancing noninvasive AI biomarkers for better patient lives. We bring artificial intelligence to imaging and lab data, re-imagining clinical assessments in serious diseases. IMVARIA serves Fibresolve -- the first AI diagnostic tool in interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF). Fibresolve is an FDA Breakthrough Device and is authorized by the FDA to serve as an adjunctive, non-invasive diagnostic tool for patients with suspected ILD and IPF. Beyond ILD and IPF, IMVARIA is developing AI biomarkers in multiple areas including oncology, pulmonology, immunology, and more.